

Contents in Print

Preface	vii
About the Editor in Chief	ix

QUALITY AND RELATED ISSUES

1. Quality Management Systems: Principles and Practice	1
<i>Sheri Goertzen, MLS(ASCP)BB, CLS(CA), COA(ASQ), and Patrick W. Ooley, MS, MLS(ASCP), CMQ/OE(ASQ)COA</i>	
Key Points	1
Concepts and Definitions	2
Quality Management Systems Approach	4
The Quality Management System in Practice Using AABB's Quality System Essentials	5
Summary	33
References	33
Appendix 1-1. Code of Federal Regulations Title 21 Quality-Related References	35
Appendix 1-2. Suggested Quality Control Performance Intervals for Equipment and Reagents	36
2. Facilities, Work Environment, and Safety	39
<i>Elizabeth S. Allen, MD, and Jovona Powelson, MLT(ASCP)</i>	
Key Points	39
Facilities	40
Safety Program	42
Fire Prevention and Electrical Safety	46
Biosafety	47
Chemical Safety	52
Radiation Safety	56
Emergency/Disaster Management	59
Shipping Hazardous Materials	60
General Waste Management	61
References	62
Appendix 2-1. Safety Regulations and Recommendations Applicable to Health-Care Settings	65
Appendix 2-2. General Guidance for Safe Work Practices, Personal Protective Equipment, and Engineering Controls	67

Appendix 2-3. Biosafety Level 2 Precautions	71
Appendix 2-4. Sample List of Hazardous Chemicals That May Be Encountered in a Blood Bank	72
Appendix 2-5. Chemical Categories and How to Work Safely with Them	74
Appendix 2-6. Incidental Spill Response	76
Appendix 2-7. Managing Hazardous Chemical Spills	79
3. Regulatory Considerations in Transfusion Medicine	81
<i>Robert A. DeSimone, MD, and Orijei C. Illoh, MD</i>	
Key Points	81
FDA Oversight of Blood Establishments	83
Medical Laboratory Laws and Regulations	91
Local Laws, Hospital Regulations, and Accreditation	92
References	92
4. Hemovigilance: Past, Present, and Future	97
<i>Barbee I. Whitaker, PhD; Mary Townsend, MD; and Erica M. Wood, AO, MBBS, FRACP, FRCPA, FAHMS</i>	
Key Points	97
International Hemovigilance—Origins of a New Concept	99
Biovigilance	102
US Hemovigilance—A Concept Takes Root	102
International Collaborations	110
The Future: Next Steps In Hemovigilance	111
References	113
Appendix 4-1. Template Form for Hospital Reporting of Adverse Events to Blood Suppliers	117
Appendix 4-2. Severity Grading Tool for Blood Donor Adverse Events	125
<hr/>	
B L O O D C O L L E C T I O N A N D T E S T I N G	
5. Allogeneic and Autologous Blood Donor Selection	129
<i>Richard R. Gammon, MD, and Mindy Goldman, MD, FRCPC</i>	
Key Points	129
Types of Blood Donors	130
Overview of Blood Donor Screening	130
Selection of Allogeneic Blood Donors	133
Abbreviated DHQ for Frequent Donors	137
DHQ Modifications with Emerging Pathogens	138
Blood-Center-Defined Donor Eligibility Criteria	138
Recipient-Specific “Designated” or “Directed” Blood Donation	140
References	142
Appendix 5-1. Code of Federal Regulations Donor-Related References	146

6. Whole Blood and Apheresis Collection of Blood Components Intended for Transfusion 149

Denese Marks, PhD, and Susanne Marschner, PhD

Key Points 149
 Donor Preparation and Care 150
 Blood Collection 152
 Blood Product Storage 158
 Postcollection Processing/Blood Component Modification 164
 Quarantine of Blood Components 170
 Labeling of Blood Components 171
 References 172

7. Infectious Disease Screening 179

Paula Saá, PhD; Matthew J. Kuehnert, MD; and Steven J. Drews, PhD, FCCM, D(ABMM)

Key Points 179
 Historical Overview of Blood Donor Screening 180
 Donor Screening Tests 184
 Residual Infectious Risks of Transfusion 203
 Screening for Specific Agents 206
 Pathogen Reduction Technology 220
 Summary 222
 References 223

B L O O D G R O U P S

8. Molecular Biology and Immunology in Transfusion Medicine 233

Catherine Hyland, PhD, and James C. Zimring, MD, PhD

Key Points 233
 Analysis of Nucleic Acids 234
 Analysis of Protein 245
 Basic Immunology 251
 References 259

9. Blood Group Genetics 265

Nicole Thornton, MSc, and Christoph Gassner, PhD, Prof

Key Points 265
 Genomic Organization and Gene Regulation 267
 Genetic Variation 275
 Inheritance of Genetic Traits 277
 Structural Variation 282
 Chimerism 284

Gene Position Effects	286
Genetic Modifiers of Blood Group Antigen Expression	286
Population Genetics	287
Relationship Testing	290
Blood Group Gene Mapping	291
Gene, Protein, and Blood Group Terminology	291
Blood Group Genomics	293
Summary	304
References	304
Appendix 9-1. Glossary of Terms Used in Blood Group Genetics	310

10. ABO and Other Carbohydrate Blood Group Systems 315

Sean R. Stowell, MD, PhD, and Connie Arthur, PhD

Key Points	315
The ABO System (001)	316
The H System (018)	332
The LE System (007)	335
I Antigen of the I Blood Group System (027) and i Antigen of the Ii Blood Group Collection	337
P1PK (003) and GLOB (028) Blood Group Systems	340
The FORS Blood Group System (031)	344
The SID Blood Group System (038)	345
References	345

11. The RH and RHAG Systems 351

Sunitha Vege, MS, and Eunike McGowan, PhD

Key Points	351
Historical Perspective	352
Terminology	355
Rh Locus	356
Rhd Genotype	358
Antigens	358
Rh Genotyping	371
Rh _{null} Syndrome and the RhAG (030) Blood Group System	372
Antibodies to Rh Blood Group System Antigens	373
Technical Considerations for Rh Typing	374
References	376

12. Other Blood Group Systems and Antigens 381

Vanja Karamatic Crew, PhD, and Sofia Lejon Crottet, PhD

Key Points	381
The MNS System (002)	382
The LU System (005)	395
The KEL (006) And Xk (019) Systems	397
The FY System (008)	401
The Jk System (009)	403

The DI System (010) 405
 The YT System (011) 407
 The XG System (012) 407
 The SC System (013) 408
 The DO System (014) 408
 The CO System (015) 409
 The LW System (016) 410
 The CH/RG System (017) 411
 The GE System (020) 411
 The CROM System (021) 412
 The KN System (022) 412
 The IN System (023) 413
 The OK System (024) 414
 The RAPH System (025) 414
 The JMH System (026) 414
 The GIL System (029) 415
 The RHAG System (030) 415
 The JR System (032) 415
 The LAN System (033) 415
 The VEL System (034) 416
 The CD59 System (035) 416
 The AUG System (036) 416
 The KANNO System (037) 417
 The CTL2 System (039) 417
 The PEL System (040) 417
 The MAM System (041) 418
 The EMM System (042) 418
 The ABCC1 System (043) 418
 The ER System (044) 418
 The CD36 System (045) 419
 The ATP11C System (046) 419
 The MAL System (047) 419
 The PIGZ System (048) 420
 Antigens That Do Not Yet Belong to a Blood Group System 420
 References 421

13. Identification of Antibodies to Red Cell Antigens 427

*Shane Grimsley, DipRCPath, FBBTS, and Jennifer O'Connor, MSTM,
 MLS(ASCP)^{CM}SBB^{CM}*

Key Points 427
 Basic Concepts in Red Cell Antigen Expression 429
 Initial Antibody Identification Considerations 430
 Basic Antibody Identification 433
 Complex Antibody Identification 441
 Selected Procedures 454
 Considerations Following Antibody Identification 461
 Immunohematology Reference Laboratories 464
 References 464
 Suggested Readings 467

14. The Positive Direct Antiglobulin Test and Immune-Mediated Hemolysis 469

*Janis R. Hamilton, MS, MLS(ASCP)SBB, and Kathy Haddaway,
MLS(ASCP)^{CM}SBB^{CM}*

Key Points	469
The DAT	471
Autoimmune Hemolytic Anemia	476
Drug-Induced Immune Hemolytic Anemia	486
References	491
Appendix 14-1. Drugs Associated with Immune Hemolytic Anemia	494

15. Platelet and Neutrophil Antigens and Antibodies 501

Ulrich J. Sachs, MD, PhD, and Yoke-Lin Fung, PhD

Key Points	501
Platelet Antigens and Antibodies	502
Neutrophil Antigens and Antibodies	514
References	522

16. The HLA System 531

*Robert Liwski, MD, PhD, FRCPC, and Jeremy Ryan Peña, MD, PhD, MS,
F(ACHI)*

Key Points	531
Biochemistry, Tissue Distribution, and Structure	532
Genetics of the MHC	537
HLA Typing	540
Other, Non-HLA Histocompatibility Determinants	543
Crossmatching and Detection of HLA Antibodies	543
The HLA System and Transfusion	544
HLA Testing and Transplantation	547
Other Clinically Significant Aspects of HLA	549
Clinical Consultation in HLA	551
Regulatory Aspects of Clinical Histocompatibility	552
Future Directions	552
Summary	553
References	553

ESSENTIALS OF TRANSFUSION PRACTICE

17. Transfusion Service Activities: Pretransfusion Testing and Management of Blood Components 557

Reggie R. Thomasson, MD, and Monica B. Pagano, MD

Key Points	557
Samples and Requests	558
Pretransfusion Testing of Recipient Blood	559

Blood and Blood Component Storage and Monitoring 563
 Pretransfusion Processing 566
 Distribution 570
 Issuing of Components 572
 Inventory Management 576
 References 577
 Appendix 17-1. Sources of False-Positive Results in Antiglobulin Testing 582
 Appendix 17-2. Sources of False-Negative Results in Antiglobulin Testing 583
 Appendix 17-3. Causes of Positive Pretransfusion Test Results. 585
 Appendix 17-4. Requirements for Storage, Transportation, and Expiration of
 Cellular Components. 587
 Appendix 17-5. Requirements for Storage, Transportation, and Expiration of
 Acellular Components 592

18. Administration of Blood Components and Infusion of Cellular Therapy Products 595

Sarah Vossoughi, MD, RN, and Monika Paroder, MD, PhD

Key Points 595
 Considerations Before Dispensing Blood Components 597
 Blood Component Transportation and Dispensing 603
 Blood Administration 604
 Documentation of the Transfusion 608
 Unique Transfusion Settings 608
 Intravenous Administration of Immune Effector Cell Cellular Therapy Products . . . 609
 Conclusion 614
 References 615

19. Transfusion Therapy: Evidence and Recommendations for Clinical Practice 619

Yunchuan Delores Mo, MD, MSc, and Cyril Jacquot, MD, PhD

Key Points 619
 Red Blood Cell Transfusion 620
 Platelet Transfusion 628
 Plasma Transfusion 635
 Cryoprecipitate Transfusion 637
 Granulocyte Transfusion 639
 Massive Transfusion Protocols 640
 References 642

20. Patient Blood Management 651

Joshua A. Nicholas, MD; Mark T. Friedman, DO; and Anil K. Panigrahi, MD, PhD

Key Points 651
 Definition and Scope of Patient Blood Management 652
 Resources to Support A PBM Program 653
 Patient Blood Management Standards and Certification 653

Methods of Patient Blood Management	653
Data Collection	679
Extremes of Transfusion	681
Summary	683
References	683

21. Hemostasis and Coagulation 691

Jeremy W. Jacobs, MD, MHS, and Geoffrey D. Wool, MD, PhD

Key Points	691
Overview of Hemostasis	692
Routine Hemostasis Testing	692
Viscoelastic Testing	699
Blood Product Usage for Bleeding/Hypocoagulable Patients	704
Blood Products for Disseminated Intravascular Coagulation	709
Summary	710
References	711

SPECIAL PATIENTS AND SITUATIONS

22. Noninfectious Complications of Blood Transfusion 717

Sandhya R. Panch, MD, MPH; Simon J. Stanworth, DPhil, FRCP, FRCPath; and Nareg Roubinian, MD, MPH

Key Points	717
Hemovigilance	718
Recognition and Evaluation of a Suspected Transfusion Reaction	725
Clinical Evaluation and Management of a Transfusion Reaction	725
Fatality Reporting Requirements	746
References	747

23. Perinatal Issues in Transfusion Practice 753

Kyle Annen, DO, CABP(AABB), QIA, and Stephanie Kinney, MD

Key Points	753
Hemolytic Disease of the Fetus and Newborn	754
Pregnancy-Related Thrombocytopenia	764
Neonatal Alloimmune Neutropenia	766
References	766

24. Neonatal and Pediatric Transfusion Practice 771

Jennifer Andrews, MD, MSc; Ross M. Fasano, MD; and Cassandra D. Josephson, MD

Key Points	771
Hematopoiesis, Coagulation, and Physiology	772
RBC Transfusion in the Newborn Period	774
RBC Transfusion in Infants Older Than 4 Months and Children	780

Platelet Transfusion in Neonates and Children 783
 Plasma and Cryoprecipitate Transfusion in Neonates and Children 786
 Granulocyte Transfusion in Neonates and Children 787
 Other Considerations in Transfusing Neonates and Children 788
 Adverse Effects and Prevention 792
 Future Research Directions for Pediatric and Neonatal Transfusion Medicine 795
 References 795

25. Therapeutic Apheresis 805

Caroline Raasch Alquist, MD, PhD, and Nicole Dodge Zantek, MD, PhD

Key Points 805
 General Principles 806
 Device Modalities 806
 Patient Evaluation and Management 808
 Vascular Access 810
 Anticoagulation 811
 Adverse Events 811
 Pediatric Apheresis 814
 Therapeutic Apheresis Indications 814
 Therapeutic Apheresis Procedure Documentation, Payment, and Provider
 Credentialing 829
 References 829

26. Collection, Processing, and Issuance of Hematological Cellular Biotherapies 837

Huy P. Pham, MD, MPH, and Laura S. Connelly-Smith, MBBCh, DM

Key Points 837
 Clinical Utility 838
 Histocompatibility, Donor Type, and Graft Source for HCT 841
 Collection 843
 Processing Hematopoietic Progenitor Cells 848
 Specialized Cell-Processing Methods 849
 Cryopreservation 850
 Quality Control 851
 Shipping and Transporting HPC Products 852
 Patient Care 852
 Regulatory and Accreditation Considerations 854
 Conclusion 855
 References 855

27. Transfusion Support for Hematopoietic Stem Cell Transplant Recipients 865

Mayrin Correa Medina, MD, PhD, and Joseph Schwartz, MD, MPH, CABP(AABB), QIA

Key Points 865
 Transfusion Support and Blood Component Selection During the Stages
 Involved in HCT 867

Special Considerations	874
References	876
28. Adverse Reactions to Cellular Immunotherapies	881
<i>Suzanne R. Thibodeaux, MD, PhD, CABP(H)(AABB), and Andrew D. Fesnak, MD</i>	
Key Points	881
Reactions Associated with Effector Function	882
Insertional Mutagenesis	888
Risks of Secondary Malignancy	889
Risks of Allogeneic Therapy	890
Infusion Reactions Unrelated to the Primary Mechanism of Action	890
Conclusion	891
References	892
29. Regulatory Considerations in Biotherapies	897
<i>Yvette C. Tanhehco, PhD, MD, MS, CABP(AABB), and J. Wade Atkins, MS, MLS(ASCP)SBB, CQA(ASQ), CABP(H)(AABB)</i>	
Key Points	897
FDA Oversight of Human Cell and Tissue Establishments	898
Accreditation	909
Immune Effector Cell Therapy	910
Cell-Based Gene Therapy	912
Commercial Manufacturing	912
International Laws and Regulations	913
References	915
30. Hospital Tissue Services and Transfusion Support for Organ Transplants	919
<i>Aleh Bobr, MD; Elizabeth P. Crowe, MD, PhD; and Annette J. Schlueter, MD, PhD</i>	
Key Points	919
Types of Transplantable Tissue	920
Tissue Donation and Processing (Functions of Tissue Suppliers)	921
Clinical Uses of Tissue Grafts	923
Federal Regulations, State Laws, and Professional Standards	927
Hospital Tissue Services	928
Transfusion Service Support for Organ Transplantation	933
References	934
31. Transfusion Practices in Resource-Limited Settings	939
<i>Bridon M'baya, MBBS, MPH; Claude T. Tagny, MD, MS, MSc; and Vernon J. Louw, MBChB, MMed (Int Med), FCP(SA), PhD(HPE)</i>	
Key Points	939
Organization and Funding of Blood Transfusion Services	940

Demand and Supply of Blood in Resource-limited Countries 943
Donor Selection and Screening 944
Collection and Processing: Whole Blood, Derivatives, and Clotting Factors 948
Infectious Disease Screening 949
Quality Assurance 951
Clinical Practices in Transfusion Medicine 952
Transfusion Research and Education 952
Research, Surveillance, and Future Directions 954
References 954

Index 959

Contents Online

www.aabb.org/methods

METHODS

1. General Laboratory Methods

- Method 1-1. Shipping Hazardous Materials
- Method 1-2. Monitoring Temperature During Shipment of Blood
- Method 1-3. Treating Incompletely Clotted Specimens
- Method 1-4. Solution Preparation Procedure
- Method 1-5. Serum Dilution Procedure
- Method 1-6. Dilution of Percentage Solutions Procedure
- Method 1-7. Preparing a 3% Red Cell Suspension
- Method 1-8. Preparing and Using Phosphate Buffer
- Method 1-9. Reading and Grading Tube Agglutination

2. Red Cell Typing Methods

- Method 2-1. Determining ABO Group of Red Cells—Slide Test
- Method 2-2. ABO Grouping—Tube Test
- Method 2-3. ABO Grouping—Microplate Test
- Method 2-4. Initial Investigation of ABO Grouping Discrepancies Procedure
- Method 2-5. Detecting Weak A and B Antigens and Antibodies by Cold Temperature Enhancement
- Method 2-6. Confirming Weak A and B Antigens Using Enzyme-Treated Red Cells
- Method 2-7. Confirming Weak A or B Subgroup by Adsorption and Elution
- Method 2-8. Testing Saliva for A, B, H, Le^a, and Le^b Antigens
- Method 2-9. Confirming Anti-A₁ in an A₂ or Weak A Subgroup
- Method 2-10. Resolving ABO Discrepancies Caused by Unexpected Alloantibodies
- Method 2-11. Determining Serum Group Without Centrifugation
- Method 2-12. Determining Rh(D) Type—Slide Test
- Method 2-13. Determining Rh(D) Type—Tube Test
- Method 2-14. Determining Rh(D) Type—Microplate Test
- Method 2-15. Testing for Weak D
- Method 2-16. Preparing and Using Lectins
- Method 2-17. Removing Autoantibody by Warm Saline Washes
- Method 2-18. Using Sulfhydryl Reagents to Disperse Autoagglutination
- Method 2-19. Using Gentle Heat Elution to Test Red Cells with a Positive DAT Result
- Method 2-20. Dissociating IgG by Chloroquine for Antigen Testing of Red Cells with a Positive DAT Result
- Method 2-21. Using Acid Glycine/EDTA to Remove Antibodies from Red Cells
- Method 2-22. Separating Transfused from Autologous Red Cells by Simple Centrifugation
- Method 2-23. Separating Transfused from Autologous Red Cells in Patients with Hemoglobin S Disease

3. Antibody Detection, Identification, and Compatibility Testing Methods

- Method 3-1. Using Immediate-Spin Compatibility Testing to Demonstrate ABO Incompatibility
- Method 3-2. Saline Indirect Antiglobulin Test Procedure
- Method 3-3. Albumin or LISS-Additive Indirect Antiglobulin Test Procedure
- Method 3-4. LISS-Suspension Indirect Antiglobulin Test Procedure
- Method 3-5. PEG Indirect Antiglobulin Test Procedure
- Method 3-6. Prewarming Procedure
- Method 3-7. Detecting Antibodies in the Presence of Rouleaux—Saline Replacement
- Method 3-8. Preparing Ficin Enzyme Stock, 1% w/v
- Method 3-9. Preparing Papain Enzyme Stock, 1% w/v
- Method 3-10. Standardizing Enzyme Procedures
- Method 3-11. Evaluating Enzyme-Treated Red Cells
- Method 3-12. One-Stage Enzyme Procedure
- Method 3-13. Two-Stage Enzyme Procedure
- Method 3-14. Performing the Direct Antiglobulin Test
- Method 3-15. Antibody Titration Procedure
- Method 3-16. Using Sulfhydryl Reagents to Distinguish IgM from IgG Antibodies
- Method 3-17. Using Plasma Inhibition to Distinguish Anti-Ch and -Rg from Other Antibodies with Similar Characteristics
- Method 3-18. Treating Red Cells Using DTT or AET
- Method 3-19. Neutralizing Anti-Sd^a with Urine
- Method 3-20. Adsorption Procedure
- Method 3-21. Using the American Rare Donor Program
- Method 3-22. Preparing C4b-Coated Red Cells to Identify Anti-Ch/Rg

4. Methods for Investigating a Positive DAT Result

- Method 4-1. Cold-Acid Elution Procedure
- Method 4-2. Glycine-HCl/EDTA Elution Procedure
- Method 4-3. Heat Elution Procedure
- Method 4-4. Lui Freeze-Thaw Elution Procedure
- Method 4-5. Cold Autoadsorption Procedure
- Method 4-6. Determining the Specificity of Cold-Reactive Autoagglutinins
- Method 4-7. Cold Agglutinin Titer Procedure
- Method 4-8. Adsorbing Warm-Reactive Autoantibodies Using Autologous Red Cells
- Method 4-9. Adsorbing Warm-Reactive Autoantibodies Using Allogeneic Red Cells
- Method 4-10. Polyethylene Glycol Adsorption Procedure
- Method 4-11. Performing the Donath-Landsteiner Test
- Method 4-12. Detecting Drug Antibodies by Testing Drug-Treated Red Cells
- Method 4-13. Detecting Drug Antibodies by Testing in the Presence of Drug

5. Methods for Detection of Hemolytic Disease of the Fetus and Newborn

- Method 5-1. Testing for Fetomaternal Hemorrhage—The Rosette Test
- Method 5-2. Testing for Fetomaternal Hemorrhage—Modified Kleihauer-Betke Test
- Method 5-3. Using Antibody Titration Studies to Assist in Early Detection of Hemolytic Disease of the Fetus and Newborn

6. Blood Collection, Component Preparation, and Storage Methods

- Method 6-1. Screening Female Donors for Acceptable Hemoglobin Level—Copper Sulfate Method
- Method 6-2. Preparing the Donor's Arm for Blood Collection
- Method 6-3. Collecting Blood and Samples for Processing and Testing
- Method 6-4. Preparing Red Blood Cells from Whole Blood
- Method 6-5. Preparing Prestorage Red Blood Cells Leukocytes Reduced from Whole Blood
- Method 6-6. Using High-Concentration Glycerol to Cryopreserve Red Cells—Meryman Method
- Method 6-7. Using High-Concentration Glycerol to Cryopreserve Red Cells—Valeri Method
- Method 6-8. Checking the Adequacy of Deglycerolization of Red Blood Cells
- Method 6-9. Preparing Fresh Frozen Plasma from Whole Blood
- Method 6-10. Preparing Cryoprecipitated AHF from Whole Blood
- Method 6-11. Thawing and Pooling Cryoprecipitated AHF
- Method 6-12. Preparing Platelets from Whole Blood
- Method 6-13. Removing Plasma from Platelets (Volume Reduction)

7. Transplantation of Cells and Tissue Methods

- Method 7-1. Infusing Cryopreserved Hematopoietic Cells
- Method 7-2. Processing Umbilical Cord Blood
- Method 7-3. Investigating Adverse Events and Infections Following Tissue Allograft Use

8. Quality Control Methods

- Method 8-1. Validating Copper Sulfate Solution
- Method 8-2. Calibrating Liquid-in-Glass Laboratory Thermometers
- Method 8-3. Calibrating Electronic Oral Thermometers
- Method 8-4. Testing Refrigerator Alarms
- Method 8-5. Testing Freezer Alarms
- Method 8-6. Calibrating Centrifuges for Platelet Separation
- Method 8-7. Calibrating a Serologic Centrifuge for Immediate Agglutination
- Method 8-8. Calibrating a Serologic Centrifuge for Washing and Antiglobulin Testing
- Method 8-9. Testing Automatic Cell Washers
- Method 8-10. Monitoring Cell Counts of Apheresis Components
- Method 8-11. Counting Residual White Cells in Leukocyte-Reduced Blood and Components—Manual Method
- Method 8-12. Saline-Washing Red Blood Cell Components

A P P E N D I C E S

- Appendix 1. Normal Values in Adults
- Appendix 2. Selected Normal Values in Children
- Appendix 3. Typical Normal Values in Tests of Hemostasis and Coagulation (Adults)
- Appendix 4. Coagulation Factor Values in Platelet Concentrates
- Appendix 5. Approximate Normal Values for Red Cell, Plasma, and Blood Volumes
- Appendix 6. Blood Group Antigens Assigned to Systems

Appendix 7. Examples of Blood Group System Gene, Antigen, and Phenotype Symbols in
Conventional and ISBT Terminology

Appendix 8. Examples of Correct and Incorrect Terminology

Appendix 9. Distribution of ABO/Rh Phenotypes by Race or Ethnicity

Appendix 10. Selected Common Abbreviations